For the first time in history, the tiniest malaria patients—newborns weighing just two to five kilograms—now have a lifesaving treatment designed specifically for them, closing a gap that has left millions of Africa’s most vulnerable infants at risk of overdose and death.
Quick Take
- WHO prequalifies Coartem Baby (artemether-lumefantrine), the first antimalarial formulation ever developed specifically for newborns and young infants weighing 2-5 kilograms
- The breakthrough addresses a critical treatment void affecting approximately 30 million babies born annually in malaria-endemic African regions
- Prior to this innovation, infants received off-label doses of medications designed for older children, dramatically increasing risks of dosing errors, adverse effects, and toxicity
- Novartis makes the treatment available on a largely not-for-profit basis in endemic areas, with WHO prequalification enabling immediate public sector procurement through UN agencies
The Invisible Crisis Nobody Was Talking About
Malaria kills more children under five than any other infectious disease in sub-Saharan Africa. Yet for decades, the smallest victims—newborns under 4.5 kilograms—faced an impossible choice: receive no treatment at all, or receive medications that were never tested on bodies their size. Doctors improvised, splitting doses designed for seven-year-olds and hoping mathematics could substitute for science. It rarely worked. Overdoses caused liver damage. Under-dosing allowed parasites to flourish. Infants died either way.
Why the Tiniest Patients Were Left Behind
The reason for this abandonment was not indifference but biology. Newborn livers process drugs differently than older children’s livers do. Pharmaceutical companies historically excluded the youngest from clinical trials, fearing toxicity they couldn’t predict or control. This created a vicious cycle: without trial data, no one could develop safe dosages. Without safe dosages, trials remained impossible. Meanwhile, 30 million babies annually in malaria zones had no approved option.
How Novartis and MMV Broke the Deadlock
Novartis partnered with Medicines for Malaria Venture, a nonprofit focused on diseases affecting the world’s poorest populations. Together they designed Coartem Baby—a dispersible formulation of artemether-lumefantrine calibrated precisely for infant metabolism. Clinical trials in eight African countries proved what seemed impossible: a malaria treatment safe and effective for the youngest patients. Swissmedic approved it in July 2025. On April 24, 2026, the World Health Organization granted prequalification, confirming the medicine met international standards for quality, safety, and efficacy.
What Prequalification Actually Means
WHO prequalification sounds bureaucratic. It is not. This designation unlocks procurement systems. UN agencies can now purchase Coartem Baby for public health programs. Donor-funded initiatives can stock it in clinics across endemic regions. The pharmaceutical gatekeeping that once kept this lifesaving drug from reaching infants simply dissolves. Novartis committed to pricing it on a largely not-for-profit basis in malaria-endemic areas, ensuring cost would not become another barrier.
The Ripple Effect Nobody Expected
This breakthrough does more than save individual infants. It establishes a precedent. Pharmaceutical companies now know that developing pediatric formulations for the world’s smallest patients is feasible, financially viable, and globally recognized. It signals that innovation for the poorest populations—those without purchasing power—can still attract serious investment and regulatory attention. That signal matters. Other neglected populations may finally receive treatments tailored to their biology rather than adapted from others’ prescriptions.
Ahead of #WorldMalariaDay (25 April), WHO has prequalified the first malaria treatment designed specifically for newborns and young infants (weighing 2–5 kg). This is a major step towards closing a critical treatment gap for the most vulnerable. Read more: https://t.co/DTKzL6rwh3… pic.twitter.com/EIeB2xLSsG
— World Health Organization (WHO) (@WHO) April 24, 2026
The WHO also rolled out new malaria diagnostic tests targeting a different parasite protein that resists the shedding mechanisms some parasites use to evade detection. These tests provide backup when standard diagnostics fail—another layer of protection for vulnerable populations who cannot afford misdiagnosis.
The Deeper Story
Coartem Baby represents something rare in global health: a solution that works because multiple actors aligned around a shared problem. Novartis invested. MMV guided. African researchers provided trial data and credibility. WHO set standards. No single entity could have achieved this alone. The treatment itself matters, certainly. But the system that produced it—collaborative, evidence-driven, oriented toward the world’s most vulnerable—may matter more.
Sources:
WHO prequalifies infant malaria treatment, rolls out new tests to tackle detection gaps
Novartis receives approval for first malaria medicine for newborn babies and young infants
First malaria treatment approved for newborns, young infants
WHO Prequalifies Novartis’ Coartem Baby for Treatment of Malaria in Newborns and Young Infants
Novartis malaria treatment Coartem® Baby receives WHO prequalification
